Cancer Research Journal
Volume 6, Issue 4, December 2018, Pages: 118-125
Received: Nov. 15, 2018;
Accepted: Dec. 5, 2018;
Published: Dec. 18, 2018
Views 490 Downloads 51
Soumaya Mohamed Eteba, Clinical Oncology & Nuclear Medicine, Mansoura University, Mansoura, Egypt
Maiy Abdul-Raheim Alshahat, Clinical Oncology & Nuclear Medicine, Mansoura University, Mansoura, Egypt
Fatma Mohamed Farouk Akl, Clinical Oncology & Nuclear Medicine, Mansoura University, Mansoura, Egypt
Nehal Kadry Mohammed, Clinical Oncology & Nuclear Medicine, Mansoura University, Mansoura, Egypt
Background & objective: Ovarian cancer is the fifth most common cancer affecting women today. The aim of this retrospective study was to present the epidemiological, pathological, clinical characteristics of epithelial ovarian cancer patients treated at Clinical Oncology and Nuclear Medicine Department, Mansoura University Hospitals in the period between January 2009 and December 2013, with evaluation of progression free survival (PFS) overall survival (OS) and prognostic factors. Patients & methods: This is a retrospective study of epithelial ovarian carcinoma women treated at Clinical Oncology and Nuclear Medicine Department, Mansoura University Hospitals (in the period between January 2009 and December 2013). Data were analyzed after being collected from the patients' medical records. Clinical abstract sheets for all cases were designed. Results: The median age was 55 years (19 – 80 years), 58 patients (39.2%) were ECOG performance status (PS) 1, whereas, 50 patients (33.8%) were PS 0 at presentation. Ninety five patients (64.2%) were postmenopausal at presentation, serous cystadenocarcinoma was the predominant histopathologic type found in 94 patients (63.5%), followed by Endometrioid type (17.5%), 79 patients (53.4%) had stage III disease and 33 patients (22.3%) had stage IV disease. The majority of patients (99 patients 66.9%) had grade III tumors, 140 patients (94.6%) in the study underwent surgical treatment, optimal debulking was done in 85 patients (60.7%), while, suboptimal debulking was done in 55 patients (39.3%), the median overall survival was 49 months, while the median progression free survival was 18 months. Conclusion: the median age was 55 years old, serous carcinoma was the predominant histopathological type. Stage III and IV predominated. Most patients underwent initially surgery followed by adjuvant chemotherapy. The median overall survival & PFS were 49 & 18 months, respectively. Age, tumor histopathology, stage, grade and tumor residue after debulking surgery were significant independent prognostic factors for epithelial ovarian cancer.
Soumaya Mohamed Eteba,
Maiy Abdul-Raheim Alshahat,
Fatma Mohamed Farouk Akl,
Nehal Kadry Mohammed,
Clinico-Epidemiological Study of Epithelial Ovarian Cancer Mansoura Experience, Cancer Research Journal.
Vol. 6, No. 4,
2018, pp. 118-125.
Siegel RL, Miller KD, and Jemal A. Cancer Statistics, 2018. CA CANCER J CLIN. 2018; 68: 7-30.
Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV. Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. J Clin Oncol. 2016; 34: 2888-2898.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61 (2): 69–90.
Siegel R, Naishadham D, Jemal A. Cancer statistics. CA: Cancer J Clin. 2013; 63 (1): 11-30.
Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, and Kamel H. Cancer Incidence in Egypt: Results of the National Population-Based Cancer Registry Program. Journal of Cancer Epidemiology Volume 2014, Article ID 437971, 1-18.
Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, et al. The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications. Arch Gynecol Obstet. 2016 Apr; 293 (4): 695-700.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. 2016. [Guideline] Available at http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Version 1.2016.
Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009; 374 (9698): 1371-1382.
Abdel Aziz KK, Shehata MA, Abdel Ghany AE, El Khouly EA, Abdel Aziz RA. Retrospective study of epithelial ovarian cancer in the Oncology Department, Menoufa University. Menoufa Medical Journal. 2014; 27: 650–656.
Karimi-Zarchi M, Mortazavizadeh SM, Bashardust N, Zakerian N, Zaidabadi M, Yazdian-Anari P, et al. The Clinicopathologic Characteristics and 5-year Survival Rate of Epithelial Ovarian Cancer in Yazd, Iran. Electronic physician. 2015; 7 (6): 1399-1406.
Paes MF, Daltoé RD, Madeira KP, Rezende LC, Sirtoli GM, Herlinger AL, et al. A retrospective analysis of clinicpathological and prognostic characteristics of ovarian tumors in the State of Espírito Santo. Brazil J Ovarian Res. 2011; 9: 4–14.
Malik IA. A prospective study of clinico-pathological features of epithelial ovarian cancer in Pakistan. J Pak Med Assoc. 2002; 52: 155-158.
Mostafa MF, El-etreby N, and Awad N. Retrospective analysis evaluating ovarian cancer cases presented at the clinical oncology department, Alexandria University. Alexandria Journal of Medicine. 2012; 48: 353–360.
Winter WE 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology. 2007; 25 (24): 3621-3627.
Nagle CM, Dixon SC, Jensen A, Kjaer SK, Modugno F, DeFazio A, et al. Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. British Journal of Cancer. 2015; 113: 817–826.
Nassar HR, Zeeneldin AA, Helal AM, Ismail YM, Elsayed AM, Elbassuiony MA, et al. Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience. Asian Pac J Cancer Prev. 2015; 16 (16): 7237-7242.
Gerestein CG, Eijkemans MJ, Bakker J, Elgersma OE, van der Burg ME, Kooi GS, et al. Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer. Anticancer Res. 2011; 31: 4043- 4049.
Teramukai S, Ochiai K, Tada H, and Fukushima M. PIEPOC: A New Prognostic Index for Advanced Epithelial Ovarian Cancer-Japan Multinational Trial Organization OC01-01. J Clin Oncol. 2007; 25 (22): 3302-3306.
du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfsterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009; 115 (6): 1234–1244.
Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 2000; 18: 3084–3092.
Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2000; 18: 106–115.
Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003; 21: 3194–3200.
Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, et al. Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol. 2012; 120 (3): 612-618.
Wright JD, Chen L, Tergas AI, Patankar S, Burke WM, Hou JW, et al. Trends in Relative Survival for Ovarian Cancer From 1975 to 2011. Obstet Gynecol. 2015; 125 (6): 1345–1352.
Wei W, Li N, Sun Y, Li B, Xu L, and Wu L. Clinical outcome and prognostic factors of patients with earlystage epithelial ovarian cancer. Oncotarget. 2017; 8 (14): 23862-23870.